Loading
Latest filing published 11 Oct 2023 for Zynerba Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of James E. Fickenscher in Zynerba Pharmaceuticals, Inc., where the filings describe the role as finance chief. Between 26 January 2022 and 10 October 2023, the trades on record add up to 7 filings.
The open-market record consists of 1 sale worth €9,777, with no purchase. Besides market trades, the filings include 5 share grants. Since January 2023: no purchases and 1 sale on the market.
The record was last updated on 11 October 2023 with a transaction in Zynerba Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations